Sep 3, 2024 | Biosimilars, Cost Savings, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Savings, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
May 13, 2024 | Diabetes, Kurt Harden, MedBen Rx, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
Sep 18, 2023 | Announcements, ICD-10 diagnosis code, MedBen Rx, Ozempic, Prescription, Ventegra
Important information for MedBen Rx clients using the Ventegra formulary: Effective October 1, an appropriate ICD-10 diagnosis code for type 2 diabetes will be required for certain Ozempic prescriptions and all other GLP-1 class medications. Ozempic and other GLP-1...
Jul 21, 2023 | Diabetes, Medicare, Ozempic, Pharmacy, Prescription, Research, Trulicity, Weight loss
A Kaiser Family Foundation (KFF) analysis of the 10 top-selling prescription drugs under Medicare Part D offers an interesting snapshot of pharmacy spend. The drugs in question comprised less than 1% of all covered drugs in 2021, but made up approximately 22% of total...
Jun 15, 2023 | Obesity, Ozempic, Pharmacy, Prescription, Rx Costs, Semaglutide, Wegovy, Weight loss
Obesity drugs are becoming big business, with a correspondingly big price tag. And with these drugs regularly making headlines, questions about whether or not health plans should cover them grow louder. The highest-profile obesity drug is semaglutide, sold under the...
